ACOG

Over the past six months, Alpha Cognition Inc. reported inducement grants in September 2026. In August 2026, the company announced and subsequently reported strong second-quarter 2026 financial results, with ZUNVEYL net product revenue increasing by 71% to $6.0 million and bottles dispensed rising by 37% to 8,294; Stonegate Capital Partners also updated coverage. In July 2026, Alpha Cognition participated in a B. Riley Securities summit and elected Dr. Robert Wills as Chairman of the Board. June 2026 saw positive pre-clinical data for ALPHA-1062 in a military model of repetitive mild traumatic brain injury. In May 2026, the company received a European Patent for ZUNVEYL. March 2026 included the reporting of fiscal 2025 financial results, showing $10.2 million in total revenue for 2025 and targeting operational profitability in 2027. The stock's 52-week range was $4.50 to $10.14, with a share price of $8.83 as of September 18, 2026, marking a 1-year change of +2.9%. The stock experienced daily moves over 5% in 53 out of 252 sessions, with the largest daily gain being +13.3% on February 6, 2026.